NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Ascendis Pharma A/S (“Ascendis” or the “Company”) (NASDAQ: ASND). Investors who purchased Ascendis securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: www.bgandg.com/asnd.
The investigation concerns whether Ascendis has violated federal securities laws.
On April 3, 2023, Ascendis issued a press release “announc[ing] that the U.S. Food & Drug Administration (FDA) has notified the Company that, as part of their ongoing review, the FDA has identified deficiencies in the Company’s New Drug Application (NDA) for TransCon PTH (palopegteriparatide) in hypoparathyroidism that at this time precludes them from holding further discussions about labeling and post-marketing requirements/commitments. The deficiencies were not disclosed in the letter.” On this news, Ascendis’s American depositary receipt (“ADR”) price fell $34.39 per ADR, or 32.07%, to close at $72.83 per ADR on April 3, 2023.
If you are aware of any facts relating to this investigation or purchased Ascendis shares, you can assist this investigation by visiting the firm’s site: www.bgandg.com/asnd. You can also contact Peretz Bronstein or his law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC represents investors in securities fraud class actions and shareholder derivative suits. The firm has recovered hundreds of millions of dollars for investors nationwide. Attorney advertising. Prior results do not guarantee similar outcomes.